Clinical trial
Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer
NCT03979508
Study timeline
Study start (actual)2020-01-10Date precision: day
Registry last updated2025-11-12
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Anatomic Stage I Breast Cancer AJCC v8unresolved
Anatomic Stage II Breast Cancer AJCC v8unresolved
Anatomic Stage III Breast Cancer AJCC v8unresolved
Breast Ductal Carcinoma In Situunresolved
Breast Fibrocystic Changeunresolved
Breast Lobular Carcinoma In Situunresolved
Invasive Breast Carcinomaunresolved
Prognostic Stage I Breast Cancer AJCC v8unresolved
Triple-Negative Breast Carcinomaunresolved
Interventions
AbemaciclibDRUG · verified · RxNorm: abemaciclib
Therapeutic Conventional SurgeryPROCEDURE
Sponsors & collaborators
Mayo Cliniclead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03979508 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.